

ASTRAZENECA PLC
Form 6-K
June 08, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of June 2018

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):
82- _____

AstraZeneca PLC

INDEX TO EXHIBITS

1.
Director Declaration

8 June 2018 07:00 BST

Director Declaration

AstraZeneca PLC (the Company) today announced that Philip Broadley, a Non-Executive Director of the Company, was appointed as a director of Stallergenes Greer plc following the conclusion of its Annual General Meeting of Shareholders with effect from 7 June 2018.

This announcement is made pursuant to Listing Rule 9.6.14 R (2).

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations

| | | |
|------------------|-----------|------------------|
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Matt Kent | UK/Global | +44 203 749 5906 |
| Gonzalo Viña | UK/Global | +44 203 749 5916 |
| Jacob Lund | Sweden | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |

Investor Relations

| | | |
|---------------------|----------------------------|------------------|
| Thomas Kudsk Larsen | | +44 203 749 5712 |
| Josie Afolabi | | +44 203 749 5631 |
| Craig Marks | Finance; Fixed Income; M&A | +44 7881 615 764 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Mitchell Chan | Oncology; Other | +1 240 477 3771 |
| Christer Gruvris | Brilinta; Diabetes | +44 203 749 5711 |
| Nick Stone | Respiratory; Renal | +44 203 749 5716 |
| Jennifer Kretzmann | Retail Investors | +44 203 749 5824 |
| US toll-free | | +1 866 381 7277 |

Adrian Kemp
Company Secretary
AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 08 June 2018

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary